Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CKPT Checkpoint Therapeutics	$4.26	$4.17	$1.87 ▼ $4.50	$370.71M	1.18	1.46 million shs	N/A
EWTX Edgewise Therapeutics	$14.30 -1.2%	$14.68	$10.60 ▼ $38.12	$1.50B	0.29	1.21 million shs	692,055 shs
INDV Indivior	$14.01 +0.8%	$11.77	$7.33 ▼ $16.69	$1.93B	0.66	1.11 million shs	878,830 shs
TVTX Travere Therapeutics	$14.31 -0.7%	$16.90	$7.36 ▼ $25.29	$1.27B	0.75	1.61 million shs	1.33 million shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CKPT Checkpoint Therapeutics	0.00%	0.00%	+2.16%	+4.67%	+119.59%
EWTX Edgewise Therapeutics	0.00%	-6.47%	+2.00%	-39.43%	-11.62%
INDV Indivior	0.00%	+0.86%	+24.98%	+42.67%	-11.66%
TVTX Travere Therapeutics	0.00%	-1.31%	-8.85%	-30.30%	+101.55%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CKPT Checkpoint Therapeutics	2.1462 of 5 stars	1.2	4.0	4.2	1.1	0.8	0.0
EWTX Edgewise Therapeutics	2.9023 of 5 stars	4.4	1.0	0.0	2.2	3.3	0.0
INDV Indivior	3.0055 of 5 stars	1.6	5.0	0.0	2.3	1.7	3.1
TVTX Travere Therapeutics	2.5103 of 5 stars	4.4	1.0	0.0	1.8	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CKPT Checkpoint Therapeutics	2.33	Hold	$4.33	1.72% Upside
EWTX Edgewise Therapeutics	2.78	Moderate Buy	$39.78	178.17% Upside
INDV Indivior	3.25	Buy	$15.00	7.07% Upside
TVTX Travere Therapeutics	2.87	Moderate Buy	$32.14	124.62% Upside

Current Analyst Ratings Breakdown

Latest CKPT, TVTX, INDV, and EWTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/11/2025	TVTX Travere Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy	$30.00
6/11/2025	TVTX Travere Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$35.00 ➝ $32.00
6/5/2025	EWTX Edgewise Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$48.00
5/16/2025	TVTX Travere Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
5/16/2025	TVTX Travere Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$30.00 ➝ $30.00
5/2/2025	TVTX Travere Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$30.00 ➝ $30.00
5/2/2025	TVTX Travere Therapeutics	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Hold ➝ Hold	$22.00 ➝ $23.00
4/30/2025	EWTX Edgewise Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$41.00
4/23/2025	TVTX Travere Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight
4/21/2025	EWTX Edgewise Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$43.00 ➝ $43.00
4/14/2025	TVTX Travere Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$47.00 ➝ $47.00

(Data available from 6/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CKPT Checkpoint Therapeutics	$41K	9,041.59	N/A	N/A	($0.47) per share	-9.06
EWTX Edgewise Therapeutics	N/A	N/A	N/A	N/A	$4.84 per share	N/A
INDV Indivior	$1.19B	N/A	$1.82 per share	7.70	($2.52) per share	N/A
TVTX Travere Therapeutics	$233.18M	5.45	N/A	N/A	$0.76 per share	18.83

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CKPT Checkpoint Therapeutics	-$51.85M	-$1.29	N/A	∞	N/A	N/A	N/A	-659.07%	8/11/2025 (Estimated)
EWTX Edgewise Therapeutics	-$133.81M	-$1.55	N/A	N/A	N/A	N/A	-30.95%	-29.45%	8/6/2025 (Estimated)
INDV Indivior	$2M	-$0.31	N/A	8.19	N/A	-4.02%	-97.29%	15.74%	7/24/2025 (Estimated)
TVTX Travere Therapeutics	-$321.55M	-$2.81	N/A	N/A	N/A	-82.88%	-1,179.73%	-41.10%	7/30/2025 (Estimated)

Latest CKPT, TVTX, INDV, and EWTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	CKPT Checkpoint Therapeutics	-$0.10	-$0.19	-$0.09	-$0.19	$4.53 million	N/A
5/8/2025	Q1 2025	EWTX Edgewise Therapeutics	-$0.45	-$0.43	+$0.02	-$0.43	N/A	N/A
5/1/2025	Q1 2025	TVTX Travere Therapeutics	-$0.55	-$0.47	+$0.08	-$0.47	$77.44 million	$81.73 million
4/24/2025	Q1 2025	INDV Indivior	$0.22	$0.41	+$0.19	$0.38	$240.13 million	$266.00 million
3/28/2025	Q4 2024	CKPT Checkpoint Therapeutics	-$0.22	-$0.69	-$0.47	-$0.69	N/A	$0.04 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CKPT Checkpoint Therapeutics	N/A	N/A	N/A	N/A	N/A
EWTX Edgewise Therapeutics	N/A	N/A	N/A	N/A	N/A
INDV Indivior	N/A	N/A	N/A	N/A	N/A
TVTX Travere Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CKPT Checkpoint Therapeutics	N/A	0.29	0.29
EWTX Edgewise Therapeutics	N/A	20.99	20.99
INDV Indivior	N/A	0.88	0.72
TVTX Travere Therapeutics	9.46	2.05	2.03

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CKPT Checkpoint Therapeutics	22.00%
EWTX Edgewise Therapeutics	N/A
INDV Indivior	60.33%
TVTX Travere Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
CKPT Checkpoint Therapeutics	2.10%
EWTX Edgewise Therapeutics	23.20%
INDV Indivior	N/A
TVTX Travere Therapeutics	4.06%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CKPT Checkpoint Therapeutics	10	87.02 million	47.81 million	Optionable
EWTX Edgewise Therapeutics	60	105.20 million	80.79 million	Optionable
INDV Indivior	1,051	N/A	N/A	Not Optionable
TVTX Travere Therapeutics	460	88.81 million	85.20 million	Optionable

CKPT, TVTX, INDV, and EWTX Headlines

Recent News About These Companies

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX

June 22 at 10:00 AM | prnewswire.com

Leerink Partnrs Has Pessimistic View of TVTX FY2025 Earnings

June 17, 2025 | americanbankingnews.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX

June 16, 2025 | accessnewswire.com

Equities Analysts Set Expectations for TVTX FY2025 Earnings

June 16, 2025 | marketbeat.com

What is HC Wainwright's Estimate for TVTX Q2 Earnings?

June 16, 2025 | marketbeat.com

Travere Therapeutics’ SWOT analysis: rare disease stock faces regulatory hurdles

June 15, 2025 | investing.com

Assenagon Asset Management S.A. Sells 116,999 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX)

June 15, 2025 | marketbeat.com

Leerink Partnrs Has Bearish Forecast for TVTX Q4 Earnings

June 15, 2025 | americanbankingnews.com

HC Wainwright Starts Travere Therapeutics, Inc. (TVTX) at Buy on FILSPARI Breakthroughs

June 14, 2025 | finance.yahoo.com

HC Wainwright Starts Travere Therapeutics, Inc. (TVTX) at Buy on FILSPARI Breakthroughs

June 13, 2025 | insidermonkey.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX

June 13, 2025 | accessnewswire.com

Q4 EPS Estimate for Travere Therapeutics Lowered by Analyst

June 13, 2025 | marketbeat.com

Cantor Fitzgerald Comments on TVTX FY2026 Earnings

June 13, 2025 | americanbankingnews.com

Travere Therapeutics (NASDAQ:TVTX) Price Target Lowered to $32.00 at Citigroup

June 13, 2025 | americanbankingnews.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX

June 12, 2025 | prnewswire.com

Travere Therapeutics (NASDAQ:TVTX) Now Covered by Analysts at HC Wainwright

June 12, 2025 | americanbankingnews.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX

June 11, 2025 | accessnewswire.com

Cantor Fitzgerald Predicts TVTX FY2026 Earnings

June 11, 2025 | marketbeat.com

Travere Therapeutics (NASDAQ:TVTX) Given "Buy" Rating at HC Wainwright

June 11, 2025 | marketbeat.com

Citigroup Issues Pessimistic Forecast for Travere Therapeutics (NASDAQ:TVTX) Stock Price

June 11, 2025 | marketbeat.com

Travere Therapeutics to Present New FILSPARI® (sparsentan) Data at the 15th International Podocyte Conference

June 11, 2025 | businesswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CKPT, TVTX, INDV, and EWTX Company Descriptions

Checkpoint Therapeutics NASDAQ:CKPT

$4.26 0.00 (0.00%)

As of 05/30/2025

Checkpoint Therapeutics, Inc., a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors. It is developing Olafertinib, which is in Phase 3 clinical trials for the treatment of adult patients with metastatic non-small cell lung cancer; CK-103 for the treatment of various advanced and metastatic solid tumor cancers; and Anti-Carbonic Anhydrase IX (CAIX) antibody, a product candidate in preclinical trials to recognize CAIX expressing cells and kill them via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. The company has licensing and collaboration agreements with Adimab, LLC for the development of Cosibelimab; NeuPharma, Inc., to develop and commercialize Olafertinib; and Jubilant Biosys Limited for the development and commercialization of novel compounds that inhibit BET bromodomains. The company was incorporated in 2014 and is based in Waltham, Massachusetts. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.

Edgewise Therapeutics NASDAQ:EWTX

$14.30 -0.17 (-1.17%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$14.68 +0.38 (+2.66%)

As of 06/20/2025 05:56 PM Eastern

Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.

Indivior NASDAQ:INDV

$14.01 +0.11 (+0.79%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$13.68 -0.33 (-2.36%)

As of 06/20/2025 04:43 PM Eastern

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.

Travere Therapeutics NASDAQ:TVTX

$14.31 -0.10 (-0.69%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$14.32 +0.01 (+0.07%)

As of 06/20/2025 04:58 PM Eastern

Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. The company's clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase (TVT-058), a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time